{"entity":{"id":"nct07589543","kind":"trial","name":"Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer","aka":[],"tldr":"A phase 1/2 trial of Cyclophosphamide, Fludarabine in ovarian cancer, run by Beijing Biotech, now recruiting.","summary":"Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer is a phase 1/2 interventional study registered as NCT07589543 by Beijing Biotech, with 42 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-DUALNK, Cyclophosphamide, Fludarabine. Conditions listed: Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07589543","url":"https://clinicaltrials.gov/study/NCT07589543"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["cyclophosphamide","fludarabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07589543","phase":"1/2","setting":"A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of Dual-Target CAR-NK Cells (EB-DUALNK) Following Lymphodepleting Chemotherapy in Adults With Recurrent or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma","sponsor":"Beijing Biotech","participation":[{"nct":"NCT07589543","source":"https://clinicaltrials.gov/study/NCT07589543","fetchedAt":"2026-10-07T16:55:50.238Z","studySha256":"04277ee80db38241fb5bd1a6ff9a08319333dae93388446716ffbf5668ec1081","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-15","leadSponsor":"Beijing Biotech","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":42,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-03-02","startedType":"actual","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07589543/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}